27
Thu, Apr
22 New Articles

Top Stories

Grid List

Bristol-Myers Squibb Company announced data from a Phase 2 study of BMS-986036, an investigational pegylated analogue of human fibroblast growth factor 21 (FGF21), a key regulator of metabolism, in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) (F1-F3).

The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MI) and SOTIO a.s. have signed a collaboration and license agreement providing SOTIO with exclusive rights to an oncology program addressing a novel target in tumor metabolism.

IBM announced that its scientists have been granted a patent on machine learning models to predict therapeutic indications and side effects from various drug information sources.

Recipharm, the contract development and manufacturing organisation (CDMO), has opened a newly built GMP suite for clinical trial material (CTM) manufacture at its facility in Research Triangle Park, North Carolina, USA.

MGC Diagnostics Corporation , a global medical technology company, today announced a new clinical study collaboration with Restech Srl to evaluate the diagnostic accuracy of the forced oscillation technique (“FOT”) to detect lung function abnormalities.

Inovio Pharmaceuticals, Inc. announced preliminary results from the expanded stage of its phase I study, EBOV-001. The expanded study examined different regimens of its Ebola DNA vaccine INO-4201 using intradermal (skin) administration.

At interpack 2017, Bosch Packaging Technology shows how industry 4.0 solutions provide higher efficiency in modern manufacturing. “All of our industry 4.0 applications focus on humans,” says Dr Stefan König, president of Bosch Packaging Technology.

Charles River Laboratories International, Inc. , a leading early-stage contract research organization announced that it has extended its longstanding, strategic, integrated drug discovery partnership with Chiesi Farmaceutici SpA in the field of respiratory disease.

Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, is pleased to update shareholders on continuing efforts to develop the oral dosing of Kevetrin.

At interpack 2017, Bosch Packaging Technology shows how Industry 4.0 solutions help to achieve higher process safety and product quality.

METTLER TOLEDO’s Rainin TerraRack™ pipette tip racks are proving advantageous for the University of Glasgow’s Centre for Cell Engineering, where scientists are investigating cell differentiation and behavior on a variety of materials. Dr Monica Tsimbouri, a research fellow at the university, explained:

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products announced that it had completed an expansion project at its Kansas City, Missouri, facility to significantly increase controlled-temperature storage capabilities for its clinical supply business.

Upcoming Events

Market Movers

Rogers Corporation

NYQ : ROG - 26 Apr, 4:02pm
92.47
+3.23 (+3.62%) After Hours:
Open 89.47 Mktcap 1.67B
High 92.79 52wk Hight 92.79
Low 89.39 52wk Low 51.98
Vol 339173 Avg Vol 120726
Eps 4.41 P/e 34.89
Currency: USD

Banco Santander, S.A. Sponsored

NYQ : SAN - 26 Apr, 4:04pm
6.50
-0.06 (-0.98%) After Hours:
Open 6.49 Mktcap 94.78B
High 6.54 52wk Hight 6.63
Low 6.47 52wk Low 3.60
Vol 5.23M Avg Vol 7.03M
Eps 0.49 P/e 15.05
Currency: USD

Merck & Company, Inc. (new)

NYQ : MRK - 26 Apr, 4:01pm
62.70
+0.40 (+0.64%) After Hours:
Open 62.63 Mktcap 172.15B
High 62.88 52wk Hight 66.80
Low 62.43 52wk Low 53.06
Vol 8.86M Avg Vol 9.02M
Eps 3.80 P/e 44.47
Currency: USD

Johnson & Johnson

NYQ : JNJ - 26 Apr, 4:00pm
123.51
+0.08 (+0.06%) After Hours:
Open 123.79 Mktcap 335.13B
High 124.26 52wk Hight 129.00
Low 123.48 52wk Low 109.32
Vol 5.02M Avg Vol 6.81M
Eps 7.10 P/e 20.76
Currency: USD

Pfizer, Inc.

NYQ : PFE - 26 Apr, 4:00pm
33.85
+0.09 (+0.27%) After Hours:
Open 33.86 Mktcap 201.47B
High 34.03 52wk Hight 37.39
Low 33.85 52wk Low 29.83
Vol 19.82M Avg Vol 23.31M
Eps 2.55 P/e 28.86
Currency: USD

Direxion Daily 10-Yr Treasury B

PCX : TYO - 26 Apr, 8:00pm
14.41
-0.08 (-0.55%) After Hours:
Open 14.51 Mktcap
High 14.56 52wk Hight 16.29
Low 14.41 52wk Low 12.60
Vol 26800 Avg Vol 10719
Eps P/e
Currency: USD
Sign up via our free email subscription service to receive notifications when new information is available.
captcha 

A global life science technology firm has surpassed the €20 million milestone for sales of its manufacturing execution system (MES) services.

Imprimis Pharmaceuticals Inc , an ophthalmology-focused pharmaceutical company, announced that it has entered into an licensing agreement for the exclusive worldwide rights to Klarity, an innovative and patented ophthalmic topical solution and gel technology for patients with dry eye disease (DED).  

Ferring Pharmaceuticals announced an agreement with Apricus Biosciences, Inc, granting Ferring global assets and rights, excluding the U.S., related to Apricus’ Vitaros.

At the discovery and early stages of drug development, the aim is to evaluate the pharmacology, pharmacokinetics and toxicology of a compound using a simple liquid formulation.

The last decade has seen an increased emphasis on research and development into personalized medicines, including cell, gene and immunotherapy treatments 

Today, the chief purpose of primary packaging is product protection. However this performance capability has become more challenging in recent years as the complexity of active pharmaceuticals and their supply chain increases.

Agenus Inc , an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of its anti-PD-1 antibody, AGEN2034.

This year’s edition of MEDICAL FAIR THAILAND is set to be its biggest yet with more than 700 international exhibitors expected. 17 national and country pavilions will present more than 5,000 state-of-the-art medical and healthcare products, equipment and solutions to a targeted audience of 10,000 medical and healthcare professionals.

Neurocrine Biosciences, Inc. announced that the U.S. FDA has approved INGREZZATM (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD).